“…Since its first pathologic description in 1978 by Stocker and Ishak, and its reported 38% overall survival (OS), 1 progress has been made with the help of multimodal therapies: chemotherapy, surgery, radiotherapy, and even primary or rescue LT, with reported OS ranging from 50 to 100%. [2][3][4][5][6][7][8][9] Because of its mixed and cystic appearance, possible intratumoral bleeding, rupture, and the lack of biologic markers, these tumors may be mistaken as mesenchymal hamartoma, hepatic hematoma, hepatoblastoma, which may lead to urgent and incomplete resection or inappropriate preoperative management. 5,10 In Europe or in America, USLs are treated according to the soft tissue sarcoma group protocols, which may include optional neoadjuvant chemotherapy, complete surgical resection, and adjuvant chemotherapy based on cyclo/ ifosfamide, vincristine, dactinomycin, plus or minus doxorobucin, and radiotherapy in case of incomplete resection or rupture (clinicaltrial.gov NCT00379457).…”